Key Points
- Orbimed Advisors LLC sold 85,918 shares of Sionna Therapeutics on July 7 at an average price of $44.86, totaling about $3.85 million. The sale was made under a pre-arranged Rule 10b5-1 trading plan.
- The transaction reduced Orbimed’s stake by 3.36%, though it still held 2.47 million shares valued at roughly $110.8 million after the sale. The filing was disclosed with the SEC.
- Sionna Therapeutics stock was trading near its 52-week high, with shares up 2.1% to $44.94, while analysts currently rate the stock a Moderate Buy with an average price target of $53.22.
Sionna Therapeutics, Inc. (NASDAQ:SION - Get Free Report) Director Orbimed Advisors Llc sold 85,918 shares of the business's stock in a transaction that occurred on Tuesday, July 7th. The shares were sold at an average price of $44.86, for a total value of $3,854,281.48. Following the sale, the director owned 2,469,959 shares of the company's stock, valued at approximately $110,802,360.74. This represents a 3.36% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Orbimed Advisors Llc also recently made the following trade(s):
- On Tuesday, June 30th, Orbimed Advisors Llc sold 115,844 shares of Sionna Therapeutics stock. The stock was sold at an average price of $45.50, for a total value of $5,270,902.00.
- On Wednesday, May 27th, Orbimed Advisors Llc sold 101 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.49, for a total transaction of $4,493.49.
- On Monday, May 11th, Orbimed Advisors Llc sold 184,639 shares of Sionna Therapeutics stock. The shares were sold at an average price of $46.22, for a total transaction of $8,534,014.58.
- On Friday, May 8th, Orbimed Advisors Llc sold 59,767 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.58, for a total value of $2,664,412.86.
- On Thursday, May 7th, Orbimed Advisors Llc sold 48,546 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.61, for a total value of $2,165,637.06.
- On Saturday, April 18th, Orbimed Advisors Llc sold 2,948 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.52, for a total transaction of $131,244.96.
- On Friday, April 17th, Orbimed Advisors Llc sold 52,397 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.68, for a total transaction of $2,341,097.96.
- On Thursday, April 16th, Orbimed Advisors Llc sold 226,906 shares of Sionna Therapeutics stock. The stock was sold at an average price of $45.34, for a total value of $10,287,918.04.
- On Wednesday, April 15th, Orbimed Advisors Llc sold 235,863 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.64, for a total value of $10,528,924.32.
- On Tuesday, April 14th, Orbimed Advisors Llc sold 47,814 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.51, for a total transaction of $2,128,201.14.
Sionna Therapeutics Stock Up 2.1%
Sionna Therapeutics stock opened at $44.94 on Friday. The firm has a 50 day moving average price of $40.28 and a 200-day moving average price of $39.54. Sionna Therapeutics, Inc. has a twelve month low of $16.38 and a twelve month high of $48.44. The company has a market capitalization of $2.03 billion, a P/E ratio of -23.28 and a beta of 1.33.
Sionna Therapeutics (NASDAQ:SION - Get Free Report) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.60) EPS for the quarter, missing analysts' consensus estimates of ($0.52) by ($0.08). Equities analysts expect that Sionna Therapeutics, Inc. will post -2.57 EPS for the current fiscal year.
Hedge Funds Weigh In On Sionna Therapeutics
Hedge funds have recently made changes to their positions in the stock. GF Fund Management CO. LTD. bought a new stake in shares of Sionna Therapeutics during the 4th quarter valued at $36,000. Russell Investments Group Ltd. purchased a new position in Sionna Therapeutics during the 3rd quarter valued at about $30,000. Balyasny Asset Management L.P. bought a new stake in shares of Sionna Therapeutics during the fourth quarter valued at about $58,000. BNP Paribas Financial Markets bought a new stake in shares of Sionna Therapeutics during the second quarter valued at about $31,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Sionna Therapeutics in the fourth quarter worth about $89,000.
Analysts Set New Price Targets
A number of research analysts have recently commented on the company. Stifel Nicolaus upped their price target on Sionna Therapeutics from $44.00 to $55.00 and gave the company a "buy" rating in a research report on Monday, May 18th. BTIG Research reissued a "buy" rating and issued a $58.00 price objective on shares of Sionna Therapeutics in a report on Wednesday, May 13th. Citizens Jmp restated a "market outperform" rating and issued a $63.00 price objective on shares of Sionna Therapeutics in a research note on Tuesday, May 26th. Wall Street Zen downgraded shares of Sionna Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, May 16th. Finally, Wedbush initiated coverage on shares of Sionna Therapeutics in a research report on Tuesday, May 5th. They set an "outperform" rating and a $53.00 target price for the company. Three investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $53.22.
Check Out Our Latest Analysis on SION
Sionna Therapeutics Company Profile
(
Get Free Report)
Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.
At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
